FDA Orange Book · active-ingredient family
Pazopanib hydrochloride
Pazopanib hydrochloride is approved as 1 brand and 6 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:VOTRIENT · NDA 022465
1
Brand (NDA)
6
Generics (ANDA)
0
Listed patents
1
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VOTRIENTRLD×2 | NOVARTIS | NDA 022465 | AB | Oct 19, 2009 |
Generic (ANDA) products (6)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| PAZOPANIB HYDROCHLORIDE | TORRENT | ANDA 219922 | — | Sep 04, 2025 | |
| PAZOPANIB HYDROCHLORIDE | EUGIA PHARMA | ANDA 219034 | AB | Dec 04, 2024 | |
| PAZOPANIB HYDROCHLORIDE | NOVUGEN | ANDA 218231 | AB | Apr 23, 2024 | |
| PAZOPANIB HYDROCHLORIDE | APOTEX | ANDA 217713 | AB | Oct 19, 2023 | |
| PAZOPANIB HYDROCHLORIDE | SUN PHARM | ANDA 215837 | AB | Oct 19, 2023 | |
| PAZOPANIB HYDROCHLORIDE | TEVA PHARMS INC | ANDA 217517 | AB | Oct 19, 2023 |
Marketing exclusivity (1)
- CGTFDA marketing exclusivity
May 06, 2026
1 mo ago
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Pazopanib hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
